Androgen receptor and prostate cancer stem cells: Biological mechanisms and clinical implications

Endocrine-Related Cancer

Volumn 22, Issue 6, 2015, Pages T209-T220

  Deng, Qu ^a,b   Tang, Dean G ^a,b,c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Androgen receptor; Cancer stem cells; Castration resistant prostate cancer; Prostate cancer; Prostate cancer stem cells

Indexed keywords

ANDROGEN RECEPTOR; ANDROGEN; AR PROTEIN, HUMAN; AR PROTEIN, MOUSE; TUMOR PROTEIN;

CANCER RESISTANCE; CANCER STEM CELL; CELL HETEROGENEITY; CLONAL EVOLUTION; HUMAN; MALE; NONHUMAN; PRIMARY TUMOR; PROSTATE CANCER; REVIEW; TREATMENT FAILURE; ADENOCARCINOMA; ANIMAL; CANCER TRANSPLANTATION; CELL CLONE; CELL SEPARATION; DEFICIENCY; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; METASTASIS; MOLECULARLY TARGETED THERAPY; MOUSE; MUTATION; NEOPLASM; ORCHIECTOMY; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; SCID MOUSE; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; XENOGRAFT;

ADENOCARCINOMA; ANDROGENS; ANIMALS; CELL SEPARATION; CLONE CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; MALE; MICE; MICE, KNOCKOUT; MICE, SCID; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASMS, HORMONE-DEPENDENT; NEOPLASTIC STEM CELLS; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 84948179534     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-15-0217     Document Type: Review

References (90)

1. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C et al. 2011 The genomic complexity of primary human prostate cancer. Nature 470 214-220. (doi:10.1038/nature09744)
2. Bisson I & Prowse DM 2009 WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Research 19 683-697. (doi:10.1038/cr.2009.43)
3. Casey OM, Fang L, Hynes PG, Abou-Kheir WG, Martin PL, Tillman HS, Petrovics G, Awwad HO, Ward Y, Lake R et al. 2012 TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation. PLo S ONE 7 e41668. (doi:10.1371/journal.pone.0041668)
4. Celia-Terrassa T, Meca-Cortes O, Mateo F, de Paz AM, Rubio N, Arnal-Estape A, Ell BJ, Bermudo R, Diaz A, Guerra-Rebollo M et al. 2012 Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. Journal of Clinical Investigation 122 1849-1868. (doi:10.1172/JCI59218)
5. Chen X, Rycaj K, Liu X & Tang DG 2013 New insights into prostate cancer stem cells. Cell Cycle 12 579-586. (doi:10.4161/cc.23721)
6. Cheng H, Snoek R, Ghaidi F, Cox ME & Rennie PS 2006 Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Research 66 10613-10620. (doi:10.1158/0008-5472.CAN-06-0028)
7. Chodak GW, Kranc DM, Puy LA, Takeda H, Johnson K & Chang C 1992 Nuclear localization of androgen receptor in heterogeneous samples of normal, hyperplastic and neoplastic human prostate. Journal of Urology 147 798-803.
8. Collins AT, Berry PA, Hyde C, Stower MJ & Maitland NJ 2005 Prospective identification of tumorigenic prostate cancer stem cells. Cancer Research 65 10946-10951. (doi:10.1158/0008-5472.CAN-05-2018)
9. Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G, Alexandrov LB, Kremeyer B, Butler A, Lynch AG, Camacho N et al. 2015 Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nature Genetics 47 367-372. (doi:10.1038/ ng.3221)
10. Craft N, Chhor C, Tran C, Belldegrun A, De Kernion J, Witte ON, Said J, Reiter RE & Sawyers CL 1999 Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Research 59 5030-5036.
11. Davis JN, Wojno KJ, Daignault S, Hofer MD, Kuefer R, Rubin MA & Day ML 2006 Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer. Cancer Research 66 11897-11906. (doi:10.1158/0008-5472.CAN-06-2497)
12. Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, Rodriguez-Barrueco R, Bonal DM, Charytonowicz E, Gladoun N, de la Iglesia-Vicente J et al. 2012 Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell 22 373-388. (doi:10.1016/j.ccr.2012.07.016)
13. Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, Garcia-Echeverria C, Schultz PG & Reddy VA 2009 The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. PNAS 106 268-273. (doi:10.1073/pnas.0810956106)
14. Dubrovska A, Elliott J, Salamone RJ, Kim S, Aimone LJ, Walker JR, Watson J, Sauveur-Michel M, Garcia-Echeverria C, Cho CY et al. 2010 Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma. Clinical Cancer Research 16 5692-5702. (doi:10.1158/1078-0432.CCR-10-1601)
15. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, Thomas GV & Sawyers CL 2003 Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4 223-238. (doi:10.1016/S1535-6108(03)00197-1)
16. Fiñones RR, Yeargin J, Lee M, Kaur AP, Cheng C, Sun P, Wu C, Nguyen C, Wang-Rodriguez J, Meyer AN et al. 2013 Early human prostate adenocarcinomas harbor androgen-independent cancer cells. PLo S ONE 8 e74438. (doi:10.1371/journal.pone.0074438)
17. Fleischmann A, Rocha C, Schobinger S, Seiler R, Wiese B & Thalmann GN 2011 Androgen receptors are differentially expressed in Gleason patterns of prostate cancer and down-regulated in matched lymph node metastases. Prostate 71 453-460. (doi:10.1002/pros.21259)
18. Ford OH III, Gregory CW, Kim D, Smitherman AB & Mohler JL 2003 Androgen receptor gene amplification and protein expression in recurrent prostate cancer. Journal of Urology 170 1817-1821. (doi:10.1097/01.ju.0000091873.09677.f4)
19. Germann M, Wetterwald A, Guzman-Ramirez N, van der Pluijm G, Culig Z, Cecchini MG, Williams ED & Thalmann GN 2012 Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer. Stem Cells 30 1076-1086. (doi:10.1002/stem.1087)
20. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC et al. 2012 The mutational landscape of lethal castration-resistant prostate cancer. Nature 487 239-243. (doi:10.1038/nature11125)
21. Gu G, Yuan J, Wills M & Kasper S 2007 Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Research 67 4807-4815. (doi:10.1158/0008-5472.CAN-06-4608)
22. Haffner MC, Mosbruger T, Esopi DM, Fedor H, Heaphy CM, Walker DA, Adejola N, Gurel M, Hicks J, Meeker AK et al. 2013 Tracking the clonal origin of lethal prostate cancer. Journal of Clinical Investigation 123 4918-4922. (doi:10.1172/JCI70354)
23. Haffner MC, De Marzo AM, Yegnasubramanian S, Epstein JI & Carter HB 2015 Diagnostic challenges of clonal heterogeneity in prostate cancer. Journal of clinical oncology 33 e38-e40. (doi:10.1200/JCO.2013.50.3540)
24. Huss WJ, Gray DR, Greenberg NM, Mohler JL & Smith GJ 2005 Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells. Cancer Research 65 6640-6650. (doi:10.1158/0008-5472.CAN-04-2548)
25. Isaacs JT & Coffey DS 1981 Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Research 41 5070-5075.
26. Jacob S, Nayak S, Fernandes G, Barai RS, Menon S, Chaudhari UK, Kholkute SD & Sachdeva G 2014 Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer. Endocrine-Related Cancer 21 473-486. (doi:10.1530/ERC-13-0514)
27. Jennbacken K, Tesan T, Wang W, Gustavsson H, Damber JE & Welen K 2010 N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer. Endocrine-Related Cancer 17 469-479. (doi:10.1677/ERC-10-0015)
28. Jeter CR, Badeaux M, Choy G, Chandra D, Patrawala L, Liu C, Calhoun-Davis T, Zaehres H, Daley GQ & Tang DG 2009 Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells 27 993-1005. (doi:10.1002/stem.29)
29. Jeter CR, Liu B, Liu X, Chen X, Liu C, Calhoun-Davis T, Repass J, Zaehres H, Shen JJ & Tang DG 2011 NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene 30 3833-3845. (doi:10.1038/onc.2011.114)
30. Jiao J, Hindoyan A, Wang S, Tran LM, Goldstein AS, Lawson D, Chen D, Li Y, Guo C, Zhang B et al. 2012 Identification of CD166 as a surface marker for enriching prostate stem/progenitor and cancer initiating cells. PLo S ONE 7 e42564. (doi:10.1371/journal.pone.0042564)
31. Jin M, Zhang T, Liu C, Badeaux MA, Liu B, Liu R, Jeter C, Chen X, Vlassov AV & Tang DG 2014 miRNA-128 suppresses prostate cancer by inhibiting BMI-1 to inhibit tumor-initiating cells. Cancer Research 74 4183-4195. (doi:10.1158/0008-5472.CAN-14-0404)
32. Kakarala M & Wicha MS 2008 Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. Journal of clinical oncology 26 2813-2820. (doi:10.1200/JCO.2008.16.3931)
33. Kerkhofs S, Denayer S, Haelens A & Claessens F 2009 Androgen receptor knockout and knock-in mouse models. Journal of molecular endocrinology 42 11-17. (doi:10.1677/JME-08-0122)
34. Kregel S, Kiriluk KJ, Rosen AM, Cai Y, Reyes EE, Otto KB, Tom W, Paner GP, Szmulewitz RZ & Vander Griend DJ 2013 Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. PLo S ONE 8 e53701. (doi:10.1371/journal.pone.0053701)
35. Kreso A & Dick JE 2014 Evolution of the cancer stem cell model. Cell Stem Cell 14 275-291. (doi:10.1016/j.stem.2014.02.006)
36. Kroon P, Berry PA, Stower MJ, Rodrigues G, Mann VM, Simms M, Bhasin D, Chettiar S, Li C, Li PK et al. 2013 JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. Cancer Research 73 5288-5298. (doi:10.1158/0008-5472.CAN- 13-0874)
37. van der Kwast TH, Schalken J, Ruizeveld deWinter JA, van Vroonhoven CC, Mulder E, Boersma W & Trapman J 1991 Androgen receptors in endocrine-therapy-resistant human prostate cancer. International Journal of Cancer 48 189-193. (doi:10.1002/ijc.2910480206)
38. Lessard J & Sauvageau G 2003 Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423 255-260. (doi:10.1038/ nature01572)
39. Li HW, Chen X, Calhoun-Davis T, Claypool K & Tang DG 2008a PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells. Cancer Research 68 1820-1825. (doi:10.1158/ 0008-5472.CAN-07-5878)
40. Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, Sikes C, Multani AS, Efstathiou E, Lopez A et al. 2008b Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9- mediated mechanisms. Journal of Clinical Investigation 118 2697-2710. (doi:10.1172/JCI33637C1)
41. Li T, Su Y, Mei Y, Leng Q, Leng B, Liu Z, Stass SA & Jiang F 2010 ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Laboratory Investigation 90 234-244. (doi:10.1038/labinvest.2009.127)
42. Linn DE, Yang X, Sun F, Xie Y, Chen H, Jiang R, Chen H, Chumsri S, Burger AM & Qiu Y 2010 A role for OCT4 in tumor initiation of drugresistant prostate cancer cells. Genes & Cancer 1 908-916. (doi:10.1177/ 1947601910388271)
43. Litvinov IV, Antony L, Dalrymple SL, Becker R, Cheng L & Isaacs JT 2006 PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor. Prostate 66 1329-1338. (doi:10.1002/pros.20483)
44. Liu C & Tang DG 2011 Micro RNA regulation of cancer stem cells. Cancer Research 71 5950-5954. (doi:10.1158/0008-5472.CAN-11-1035)
45. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S et al. 2011 The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nature Medicine 17 211-215. (doi:10.1038/nm.2284)
46. Liu C, Kelnar K, Vlassov AV, Brown D, Wang J & Tang DG 2012 Distinct microRNA expression profiles in prostate cancer stem/progenitor cells and tumor-suppressive functions of let-7. Cancer Research 72 3393-3404. (doi:10.1158/0008-5472.CAN-11-3864)
47. Liu X, Chen X, Chen X, Rycaj K, Chao HP, Deng Q, Jeter C, Liu C, Honorio S & Li H 2015 Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells. Oncotarget [in press].
48. Loughran SJ, Kruse EA, Hacking DF, de Graaf CA, Hyland CD, Willson TA, Henley KJ, Ellis S, Voss AK, Metcalf D et al. 2008 The transcription factor Erg is essential for definitive hematopoiesis and the function of adult hematopoietic stem cells. Nature Immunology 9 810-819. (doi:10.1038/ ni.1617)
49. Lukacs RU, Memarzadeh S, Wu H & Witte ON 2010 Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell 7 682-693. (doi:10.1016/j.stem.2010.11.013)
50. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, Di Paola RS & Yao SL 2014 Fifteen-year survival outcomes following primary androgendeprivation therapy for localized prostate cancer. JAMA Internal Medicine 174 1460-1467. (doi:10.1001/jamainternmed.2014.3028)
51. Masai M, Sumiya H, Akimoto S, Yatani R, Chang CS, Liao SS & Shimazaki J 1990 Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates. Prostate 17 293-300. (doi:10.1002/pros.2990170405)
52. Miki J, Furusato B, Li H, Gu Y, Takahashi H, Egawa S, Sesterhenn IA, Mc Leod DG, Srivastava S & Rhim JS 2007 Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Research 67 3153-3161. (doi:10.1158/0008-5472.CAN-06-4429)
53. Minner S, Enodien M, Sirma H, Luebke AM, Krohn A, Mayer PS, Simon R, Tennstedt P, Muller J, Scholz L et al. 2011 ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clinical Cancer Research 17 5878-5888. (doi:10.1158/1078-0432.CCR-11-1251)
54. Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT et al. 2009 Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clinical Cancer Research 15 4706-4711. (doi:10.1158/ 1078-0432.CCR-08-2927)
55. Ng AP, Loughran SJ, Metcalf D, Hyland CD, de Graaf CA, Hu Y, Smyth GK, Hilton DJ, Kile BT & Alexander WS 2011 Erg is required for self-renewal of hematopoietic stem cells during stress hematopoiesis in mice. Blood 118 2454-2461. (doi:10.1182/blood-2011-03-344739)
56. Niu Y, Altuwaijri S, Yeh S, Lai KP, Yu S, Chuang KH, Huang SP, Lardy H & Chang C 2008 Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. PNAS 105 12188-12193. (doi:10.1073/ pnas.0804701105)
57. Park IK, Qian D, Kiel M, Becker MW, Pihalja M, Weissman IL, Morrison SJ & Clarke MF 2003 Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423 302-305. (doi:10.1038/nature01587)
58. Patrawala L, Calhoun T, Schneider-Broussard R, Zhou J, Claypool K & Tang DG 2005 Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2C and ABCG2- cancer cells are similarly tumorigenic. Cancer Research 65 6207-6219. (doi:10.1158/0008-5472. CAN-05-0592)
59. Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra D, Zhou J, Claypool K et al. 2006 Highly purified CD44C prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25 1696-1708. (doi:10.1038/sj.onc.1209327)
60. Patrawala L, Calhoun-Davis T, Schneider-Broussard R & Tang DG 2007 Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44Ca2b1Ccell population is enriched in tumor-initiating cells. Cancer Research 67 6796-6805. (doi:10.1158/0008-5472.CAN-07-0490)
61. Polson ES, Lewis JL, Celik H, Mann VM, Stower MJ, Simms MS, Rodrigues G, Collins AT & Maitland NJ 2013 Monoallelic expression of TMPRSS2/ERG in prostate cancer stem cells. Nature Communications 4 1623. (doi:10.1038/ncomms2627)
62. Puisieux A, Brabletz T & Caramel J 2014 Oncogenic roles of EMT-inducing transcription factors. Nature Cell Biology 16 488-494. (doi:10.1038/ ncb2976)
63. Qin J, Liu X, Laffin B, Chen X, Choy G, Jeter CR, Calhoun-Davis T, Li H, Palapattu GS, Pang S et al. 2012 The PSA-/lo prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell 10 556-569. (doi:10.1016/j.stem. 2012.03.009)
64. Quigley CA, De Bellis A, Marschke KB, el-Awady MK, Wilson EM & French FS 1995 Androgen receptor defects: historical, clinical, and molecular perspectives. Endocrine Reviews 16 271-321. (doi:10.1210/edrv-16-3-271)
65. Rajasekhar VK, Studer L, Gerald W, Socci ND & Scher HI 2011 Tumourinitiating stem-like cells in human prostate cancer exhibit increased NF-kappaB signalling. Nature Communications 2 162. (doi:10.1038/ ncomms1159)
66. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G et al. 2015 Integrative clinical genomics of advanced prostate cancer. Cell 161 1215-1228. (doi:10.1016/j.cell.2015.05.001)
67. Ruizeveld de Winter JA, Trapman J, Brinkmann AO, Boersma WJ, Mulder E, Schroeder FH, Claassen E & van der Kwast TH 1990 Androgen receptor heterogeneity in human prostatic carcinomas visualized by immunohistochemistry. Journal of Pathology 160 329-332. (doi:10.1002/path. 1711600409)
68. Ruizeveld de Winter JA, Janssen PJ, Sleddens HM, Verleun-Mooijman MC, Trapman J, Brinkmann AO, Santerse AB, Schroder FH & van der Kwast TH 1994 Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. American Journal of Pathology 144 735-746.
69. Rybak AP, Bristow RG & Kapoor A 2015 Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression. Oncotarget 6 1900-1919.
70. Rycaj K & Tang DG 2015 Cell-of-origin of cancer versus cancer stem cells: Assays and interpretations. Cancer Research [in press]. (doi:10.1158/ 0008-5472.CAN-15-0798)
71. Sadi MV & Barrack ER 1993 Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Heterogeneity as a predictor of response to hormonal therapy. Cancer 71 2574-2580. (doi:10.1002/1097-0142(19930415)71:8!2574::AIDCNCR2820710823O3.0. CO;2-1)
72. Sadi MV, Walsh PC & Barrack ER 1991 Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer 67 3057-3064. (doi:10.1002/1097-0142(19910615)67:12!3057::AIDCNCR2820671221O3.0. CO;2-S)
73. Schroeder A, Herrmann A, Cherryholmes G, Kowolik C, Buettner R, Pal S, Yu H, Müller-Newen G & Jove R 2014 Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling. Cancer Research 74 1227-1237. (doi:10.1158/ 0008-5472.CAN-13-0594)
74. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA et al. 2004 Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Research 64 9209-9216. (doi:10.1158/ 0008-5472.CAN-04-2442)
75. Simanainen U, Allan CM, Lim P, Mc Pherson S, Jimenez M, Zajac JD, Davey RA & Handelsman DJ 2007 Disruption of prostate epithelial androgen receptor impedes prostate lobe-specific growth and function. Endocrinology 148 2264-2272. (doi:10.1210/en.2006-1223)
76. Snoek R, Cheng H, Margiotti K, Wafa LA, Wong CA, Wong EC, Fazli L, Nelson CC, Gleave ME & Rennie PS 2009 In vivo knockdown of the androgen receptor results in growth inhibition and regression of wellestablished, castration-resistant prostate tumors. Clinical Cancer Research 15 39-47. (doi:10.1158/1078-0432.CCR-08-1726)
77. Sun Y, Wang BE, Leong KG, Yue P, Li L, Jhunjhunwala S, Chen D, Seo K, Modrusan Z, Gao WQ et al. 2012 Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Research 72 527-536. (doi:10.1158/0008-5472.CAN-11-3004)
78. Sun F, Chen HG, Li W, Yang X, Wang X, Jiang R, Guo Z, Chen H, Huang J, Borowsky AD et al. 2014 Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine/ paracrine factors. Journal of Biological Chemistry 289 1529-1539. (doi:10.1074/jbc.M113.492140)
79. Tam WL & Weinberg RA 2013 The epigenetics of epithelial-mesenchymal plasticity in cancer. Nature Medicine 19 1438-1449. (doi:10.1038/ nm.3336)
80. Tamburrino L, Salvianti F, Marchiani S, Pinzani P, Nesi G, Serni S, Forti G & Baldi E 2012 Androgen receptor (AR) expression in prostate cancer and progression of the tumor: lessons from cell lines, animal models and human specimens. Steroids 77 996-1001. (doi:10.1016/j.steroids. 2012.01.008)
81. Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, Fazli L, Wada R, Huang J, Vessella RL et al. 2010 Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nature Medicine 16 1414-1420. (doi:10.1038/ nm.2236)
82. Tang DG 2012 Understanding cancer stem cell heterogeneity and plasticity. Cell Research 22 457-472. (doi:10.1038/cr.2012.13)
83. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R et al. 2005 Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 644-648. (doi:10.1126/science.1117679)
84. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, Thomas GV, Li G, Roy-Burman P, Nelson PS et al. 2003 Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4 209-221. (doi:10.1016/S1535-6108(03)00215-0)
85. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M et al. 2009a Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138 245-256. (doi:10.1016/j.cell.2009.04.056)
86. Wang X, Kruithof-deJulio M, Economides KD, Walker D, Yu H, Halili MV, Hu YP, Price SM, Abate-Shen C & Shen MM 2009b A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 461 495-500. (doi:10.1038/nature08361)
87. Wu CT, Altuwaijri S, Ricke WA, Huang SP, Yeh S, Zhang C, Niu Y, Tsai MY & Chang C 2007 Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor. PNAS 104 12679-12684. (doi:10.1073/pnas.0704940104)
88. Wu K, Gore C, Yang L, Fazli L, Gleave M, Pong RC, Xiao G, Zhang L, Yun EJ, Tseng SF et al. 2012 Slug, a unique androgen-regulated transcription factor, coordinates androgen receptor to facilitate castration resistance in prostate cancer. Molecular Endocrinology 26 1496-1507. (doi:10.1210/ me.2011-1360)
89. Yang T, Rycaj K, Liu ZM & Tang DG 2014 Cancer stem cells: constantly evolving and functionally heterogeneous therapeutic targets. Cancer Research 74 2922-2927. (doi:10.1158/0008-5472.CAN-14-0266)
90. Zhau HY, Chang SM, Chen BQ, Wang Y, Zhang H, Kao C, Sang QA, Pathak SJ & Chung LW 1996 Androgen-repressed phenotype in human prostate cancer. PNAS 93 15152-15157. (doi:10.1073/pnas.93. 26.15152)